Emil_Frei_III

Emil Frei

Emil Frei

American physician and oncologist


Emil "Tom" Frei III (February 21, 1924 – April 30, 2013) was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana–Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.[1]

Quick Facts Born, Died ...

Early life and education

Frei was born in 1924 in St. Louis.[2] His family owned the stained glass manufacturer Emil Frei & Associates. Frei completed an accelerated pre-med Colgate University in 1944 after only 2 years of study[3] and his medical degree from Yale University in 1948.

Career

He interned at Firmin Desloge Hospital, now St. Louis University Hospital in St. Louis, Missouri and served as a physician in the Korean War. He worked at the National Cancer Institute from 1955 to 1965 and the M. D. Anderson Cancer Center from 1965 to 1972; while at M.D. Anderson he was the founding director of the Department of Development Therapeutics, which evolved into the Clinical Research Center. He served as physician-in-chief at the Dana-Farber Institute from 1972 to 1991. He is best known for his work on the treatment of lymphomas and childhood and adult leukemia.[4] His groundbreaking research into then-controversial combination chemotherapy, including the VAMP regimen, earned him many awards.[3][5]

He coauthored "Cancer Medicine" with Dr. James F. Holland.

Involvement in Cancer Cooperative Group Research

Frei was one of the founders of the Acute Leukemia Group B which later evolved into the Cancer and Leukemia Group B (CALGB). He served as the group chair for 16 years, from 1956 to 1963, and again from 1981 to 1990.[6]

Journal of Clinical Oncology

He coined the Journal of Clinical Oncology in 1981, journal published first issue in 1983 in association with American Society of Clinical Oncology.[7]

Recognition

Dr. Emil Frei with Edna Jones in 1972

In 1972 he received the Lasker-DeBakey Clinical Medical Research Award from the Lasker Foundation "for his outstanding contribution in application of the concept of combination chemotherapy for lymphoma and acute adult leukemia."[8] Other awards included the Jeffrey A. Gottlieb Memorial Award (1978); NIH Distinguished Alumni Award (1990); Fellow, American Academy of Arts and Sciences (1999); Pollin Prize for Pediatric Research (2003); and AARC Lifetime Achievement Award (2004).[9]

Death

Frei died of Parkinson's disease at his home in Oak Park, Illinois on April 30, 2013. He was 89.[2]

See also


References

  1. "Official biography". Dana–Farber Cancer Institute. Archived from the original on 4 March 2016. Retrieved 13 March 2013.
  2. Fox, Margalit (4 May 2013). "Emil Frei III, Who Put Cancer Cures in Reach, Dies at 89". The New York Times. Retrieved 5 May 2013.
  3. "Emil Frei III". Animals in Research. National Institutes of Health. Archived from the original on 30 October 2011. Retrieved 13 March 2013.
  4. Mukherjee, Siddhartha (2011). The Emperor of All Maladies. NY: Scribbler. pp. 139–142.
  5. "History of CALGB". Archived from the original on 2015-09-07. Retrieved 2013-05-01.
  6. Bertino, Joseph R. (1983). "Editorial: A journal for Oncologists". Journal of Clinical Oncology. 1 (1): 1. doi:10.1200/JCO.1983.1.1.1.
  7. "Lasker Award". National Institutes of Health. Retrieved 13 March 2013.
  8. "Biographical note: Emil Frei, III". Making Cancer History Voices Collection. University of Texas Archival Resources Online. Retrieved 13 March 2013.

Share this article:

This article uses material from the Wikipedia article Emil_Frei_III, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.